We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Port Erin | LSE:PEBI | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.50 | 4.00 | 5.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMPEBI
RNS Number : 9337U
Port Erin Biopharma Investments Ltd
18 July 2018
18 July 2018
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 30 June 2018
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2018 was 8.40 pence per share, including un-invested cash of GBP555,293. The portfolio is valued under IFRS at bid price.
Net Assets stand at GBP2.0 million including investments of GBP1.2 million. This quarter's NAV represents an increase of 1.57% from the previous valuation of 8.27 pence per share, which included un-invested cash of GBP502,705. No management fee is due to Shellbay Investments Limited.
Regent Pacific Group Limited value increased by 21% in the period under review, following the positive annual financial results published in March 2018 highlighting the news regarding the global launches of Fortacin(TM).
As previously announced in June 2018, we disposed of approximately half of our holding in Summit Therapeutics plc before the announcement of the failure of their clinical trial to meet primary or secondary endpoints. This sale generated GBP118,701.67 net cash to add to our reserves.
Insilico Medicine Inc, a Baltimore based next generation artificial intelligence company, specializes in the application of deep learning for target identification, drug discovery and aging research. In June 2018, Insilco announced that it has entered into a collaboration agreement with WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform, to potentially improve the efficiency of drug discovery and increase productivity.
AgeX Therapeutics, Inc announced in May 2018 the award of a grant of approximately US$386,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health. The grant provides funding for continued development of the company's technologies for addressing age-related degenerative diseases. In June 2018, AgeX announced it had closed a US$5 million equity financing through the sale of common shares to Juvenescence Limited.
Our other holdings in unquoted companies continue to show promise. In particular, Cytox Limited announced in May 2018 that it has launched a collaboration agreement with Mayo Clinic to evaluate novel genetic based approaches for assessing Alzheimer's risk."
Unaudited to 30 June 2018 GBP Fixed Assets Investments 1,174,946 Current Assets Loan receivable 226,584 Sundry Debtors 14,480 Uninvested cash 555,293 Current Liabilities Creditors: amounts due (23,759) ----------------- 1,947,544 Capital and Reserves Share Capital 23 Share Premium 1,890,142 Reserves 57,379 ----------------- 1,947,544 Shares in Issue 23,195,558 Net Asset Value per share 8.40 pence
Portfolio Details
Investments as at 30 June 2018 Value % of Total Portfolio Regent Pacific Group Limited GBP465,974 39.66% Summit Therapeutics plc GBP21,338 1.82% SalvaRX Group plc GBP54,444 4.63% Other quoted holdings GBP35,090 2.99% Other unquoted holdings GBP598,100 50.90% Total GBP1,174,946 100.00%
For further information, please contact:
Port Erin Biopharma Beaumont Cornish Limited Optiva Securities Investments Limited Limited The Company Nomad Broker Denham Eke Roland Cornish/James Biddle Jeremy King/Ed McDermott +44 (0) 1624 639396 +44 (0) 207 628 3396 +44 (0) 203 137 1904
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NAVDMGMNDNFGRZM
(END) Dow Jones Newswires
July 18, 2018 02:00 ET (06:00 GMT)
1 Year Port Erin Chart |
1 Month Port Erin Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions